|
[1]
|
Impact of GSTT1 and GSTM1 Polymorphisms in the Susceptibility to
Philadelphia Negative Chronic Myeloid Leukaemia
Current Cancer Drug Targets,
2023
DOI:10.2174/1568009623666221027103845
|
|
|
|
|
[2]
|
Inferring cancer common and specific gene networks via multi-layer joint graphical model
Computational and Structural Biotechnology Journal,
2023
DOI:10.1016/j.csbj.2023.01.017
|
|
|
|
|
[3]
|
M2PP: a novel computational model for predicting drug-targeted pathogenic proteins
BMC Bioinformatics,
2022
DOI:10.1186/s12859-021-04522-9
|
|
|
|
|
[4]
|
M2PP: a novel computational model for predicting drug-targeted pathogenic proteins
BMC Bioinformatics,
2022
DOI:10.1186/s12859-021-04522-9
|
|
|
|
|
[5]
|
Effects of GSTP1 Ile105Val polymorphism on both susceptibility and treatment response of chronic myeloid leukemia
Meta Gene,
2021
DOI:10.1016/j.mgene.2021.100865
|
|
|
|
|
[6]
|
Effects of GSTP1 Ile105Val polymorphism on both susceptibility and treatment response of chronic myeloid leukemia
Meta Gene,
2021
DOI:10.1016/j.mgene.2021.100865
|
|
|
|
|
[7]
|
Effect of Glutathione S-transferase mu 1 ( GSTM1 ) gene polymorphism on chronic myeloid leukemia risk and Imatinib treatment response
Meta Gene,
2017
DOI:10.1016/j.mgene.2017.02.006
|
|
|
|
|
[8]
|
Biomarkers of susceptibility following benzene exposure: influence of genetic polymorphisms on benzene metabolism and health effects
Biomarkers in Medicine,
2016
DOI:10.2217/bmm.15.106
|
|
|
|
|
[9]
|
GSTM1 and GSTP1 Genetic Polymorphisms and Their Associations With Acute Lymphoblastic Leukemia Susceptibility in a Jordanian Population
Journal of Pediatric Hematology/Oncology,
2016
DOI:10.1097/MPH.0000000000000609
|
|
|
|
|
[10]
|
GSTM1 and GSTP1 Genetic Polymorphisms and Their Associations With Acute Lymphoblastic Leukemia Susceptibility in a Jordanian Population
Journal of Pediatric Hematology/Oncology,
2016
DOI:10.1097/MPH.0000000000000609
|
|
|
|
|
[11]
|
Effect of interaction of glutathione S-transferases (T1 and M1) on the hematologic and cytogenetic responses in chronic myeloid leukemia patients treated with imatinib
Medical Oncology,
2014
DOI:10.1007/s12032-014-0047-z
|
|
|
|